160 related articles for article (PubMed ID: 23415672)
1. Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy.
Braicu EI; Fotopoulou C; Chekerov R; Richter R; Blohmer J; Kümmel S; Stamatian F; Yalcinkaya I; Mentze M; Lichtenegger W; Sehouli J
Cytokine; 2013 Mar; 61(3):755-8. PubMed ID: 23415672
[TBL] [Abstract][Full Text] [Related]
2. Role of serum VEGFA, TIMP2, MMP2 and MMP9 in monitoring response to adjuvant radiochemotherapy in patients with primary cervical cancer--results of a companion protocol of the randomized NOGGO-AGO phase III clinical trial.
Braicu EI; Gasimli K; Richter R; Nassir M; Kümmel S; Blohmer JU; Yalcinkaya I; Chekerov R; Ignat I; Ionescu A; Mentze M; Fotopoulou C; Pop C; Lichtenegger W; Sehouli J; ;
Anticancer Res; 2014 Jan; 34(1):385-91. PubMed ID: 24403492
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological variables predictive of clinical outcome in patients with FIGO stage Ib2-IIb cervical cancer treated with cisplatin-based neoadjuvant chemotherapy followed by radical hysterectomy.
Gadducci A; Teti G; Barsotti C; Tana R; Fanucchi A; Orlandini C; Fabrini MG; Genazzani AR
Anticancer Res; 2010 Jan; 30(1):201-8. PubMed ID: 20150636
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study.
Blohmer JU; Paepke S; Sehouli J; Boehmer D; Kolben M; Würschmidt F; Petry KU; Kimmig R; Elling D; Thomssen C; von Minckwitz G; Möbus V; Hinke A; Kümmel S; Budach V; Lichtenegger W; Schmid P
J Clin Oncol; 2011 Oct; 29(28):3791-7. PubMed ID: 21860000
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study.
Sehouli J; Runnebaum IB; Fotopoulou C; Blohmer U; Belau A; Leber H; Hanker LC; Hartmann W; Richter R; Keyver-Paik MD; Oberhoff C; Heinrich G; du Bois A; Olbrich C; Simon E; Friese K; Kimmig R; Boehmer D; Lichtenegger W; Kuemmel S
Ann Oncol; 2012 Sep; 23(9):2259-2264. PubMed ID: 22357252
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant intraarterial chemotherapy followed by radical hysterectomy and/or radiotherapy for locally advanced cervical cancer.
Sugiyama T; Nishida T; Hasuo Y; Fujiyoshi K; Yakushiji M
Gynecol Oncol; 1998 May; 69(2):130-6. PubMed ID: 9600820
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
[TBL] [Abstract][Full Text] [Related]
8. Serum nucleosomes during neoadjuvant chemotherapy in patients with cervical cancer. Predictive and prognostic significance.
Trejo-Becerril C; Oñate-Ocaña LF; Taja-Chayeb L; Vanoye-Carlo A; Cetina L; Duenas-Gonzalez A
BMC Cancer; 2005 Jun; 5():65. PubMed ID: 15982417
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience.
Kim HS; Kim JW; Wu HG; Chung HH; Park NH; Song YS; Kang SB; Lee HP
J Obstet Gynaecol Res; 2010 Jun; 36(3):598-604. PubMed ID: 20598043
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of paclitaxel and carboplatin as a regimen for postoperative concurrent chemoradiotherapy of high risk uterine cervix cancer.
Kim K; Chie EK; Wu HG; Ha SW; Kim JS; Kim IA; Lee HP
Gynecol Oncol; 2006 Jun; 101(3):398-402. PubMed ID: 16330087
[TBL] [Abstract][Full Text] [Related]
11. Glucose as a prognostic factor in non-diabetic women with locally advanced cervical cancer (IIB-IVA).
Lee YY; Choi CH; Kim CJ; Song TJ; Kim MK; Kim TJ; Lee JW; Kim BG; Lee JH; Bae DS
Gynecol Oncol; 2010 Mar; 116(3):459-63. PubMed ID: 20004008
[TBL] [Abstract][Full Text] [Related]
12. Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients.
Ryu HS; Chun M; Chang KH; Chang HJ; Lee JP
Gynecol Oncol; 2005 Feb; 96(2):490-5. PubMed ID: 15661240
[TBL] [Abstract][Full Text] [Related]
13. Matched-case comparison for the efficacy of neoadjuvant chemotherapy before surgery in FIGO stage IB1-IIA cervical cancer.
Kim HS; Kim JY; Park NH; Kim K; Chung HH; Kim YB; Kim JW; Kim HJ; Song YS; Kang SB
Gynecol Oncol; 2010 Nov; 119(2):217-24. PubMed ID: 20705335
[TBL] [Abstract][Full Text] [Related]
14. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
15. Ten-year survival of patients with locally advanced, stage ib-iib cervical cancer after neoadjuvant chemotherapy and radical hysterectomy.
Hwang YY; Moon H; Cho SH; Kim KT; Moon YJ; Kim SR; Kim DS
Gynecol Oncol; 2001 Jul; 82(1):88-93. PubMed ID: 11426967
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy plus radical surgery followed by chemotherapy in locally advanced cervical cancer.
Angioli R; Plotti F; Montera R; Aloisi A; Luvero D; Capriglione S; Terranova C; De Cicco Nardone C; Muzii L; Benedetti-Panici P
Gynecol Oncol; 2012 Nov; 127(2):290-6. PubMed ID: 22819938
[TBL] [Abstract][Full Text] [Related]
17. Concurrent paclitaxel/cisplatin chemoradiotherapy with or without consolidation chemotherapy in high-risk early-stage cervical cancer patients following radical hysterectomy: preliminary results of a phase III randomized study.
Zhao H; Li L; Su H; Lin B; Zhang X; Xue S; Fei Z; Zhao L; Pan Q; Jin X; Xie C
Oncotarget; 2016 Oct; 7(43):70969-70978. PubMed ID: 27391158
[TBL] [Abstract][Full Text] [Related]
18. Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer.
Havrilesky LJ; Leath CA; Huh W; Calingaert B; Bentley RC; Soper JT; Alvarez Secord A
Gynecol Oncol; 2004 May; 93(2):429-34. PubMed ID: 15099957
[TBL] [Abstract][Full Text] [Related]
19. Outcomes and toxicities for the treatment of stage IVB cervical cancer.
Hwang JH; Lim MC; Seo SS; Kang S; Park SY; Kim JY
Arch Gynecol Obstet; 2012 Jun; 285(6):1685-93. PubMed ID: 22173823
[TBL] [Abstract][Full Text] [Related]
20. Cervical cancer: combined modality therapy.
Grigsby PW
Cancer J; 2001; 7 Suppl 1():S47-50. PubMed ID: 11504285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
